Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the efficiency of an oral regimen in newly diagnosed Waldenström macroglobulinemia: thalidomide plus cyclophosphamide and dexamethasone following by thalidomide and prednisone maintenance therapy.
Full description
Enrolled patients will accept maximum 8 cycles of thalidomide plus cyclophosphamide and dexamethasone. if a partial remission response or better is achieved, thalidomide plus prednisone maintenance therapy will be given for no more than two years.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
44 participants in 1 patient group
Loading...
Central trial contact
Lugui Qiu, Doc; Shuhua Yi, Doc
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal